金河生物(002688) - 2025 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2025 was CNY 645,942,171.20, representing a 9.20% increase year-over-year, while year-to-date revenue reached CNY 2,036,199,952.22, up 22.86% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 1,149,590.21, a significant decrease of 94.94% year-over-year, with year-to-date net profit at CNY 139,068,189.51, an increase of 22.25%[5] - The basic and diluted earnings per share for Q3 2025 were both CNY 0.0015, down 94.90% from the same quarter last year[5] - The net profit for Q3 2025 was CNY 134,780,194.66, an increase of 19.3% compared to CNY 113,065,440.05 in the same period last year[37] - The total profit for the period was CNY 160,750,511.35, an increase of 29.3% from CNY 124,210,778.64 in the same quarter last year[37] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,584,971,110.18, a decrease of 1.16% from the end of the previous year[5] - Total liabilities decreased to ¥2,985,226,288.81 from ¥3,150,724,813.22, a decline of 5.2%[34] - The total equity attributable to shareholders increased by 4.58% year-over-year, reaching CNY 2,349,509,857.26[5] - The total equity attributable to shareholders rose to ¥2,349,509,857.26 from ¥2,246,607,845.93, an increase of 4.6%[35] Cash Flow - The company’s cash flow from operating activities for the year-to-date was CNY 364,247,585.56, reflecting a decrease of 4.04%[5] - Cash flow from financing activities decreased by 780,066,049.21 yuan, a decline of 42.28%, primarily due to reduced borrowing and repayment of more maturing debts[23] - Net cash increase in cash and cash equivalents decreased by 296,085,837.75 yuan, a decline of 130.21%, mainly due to reduced financing activities[24] - The net cash flow from operating activities was CNY 364,247,585.56, slightly down from CNY 379,581,732.41 in the previous year[39] - The cash and cash equivalents at the end of the period were CNY 519,657,637.46, a decrease from CNY 725,025,045.03 year-over-year[39] Expenses and Impairments - Research and development expenses increased by 51.10% year-over-year, amounting to CNY 28,951,969.12, as the company enhanced its competitiveness through increased investment[15] - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which fell by 118.45% year-over-year to CNY -3,246,231.76 for Q3 2025[5] - Income tax expenses increased by 14,824,978.10 yuan, an increase of 133.02%, driven by improved overall performance and profit growth, particularly from subsidiary PharmaWay[17] - Cash paid for various taxes increased by 43,029,542.50 yuan, a rise of 99.93%, reflecting the company's sustained operational performance[19] - Credit impairment losses decreased by 2,086,965.35 yuan, a reduction of 58.41%, mainly due to intensified collection efforts resulting in recovery of long-overdue receivables[16] - Asset impairment losses decreased by 16,236,415.71 yuan, a decline of 93.64%, attributed to reduced provisions for inventory write-downs as prices rebounded and unit costs decreased[16] Stock and Shareholder Information - Total number of common shareholders at the end of the reporting period was 50,527[26] - The company approved the release of 4,826,000 restricted stocks, accounting for 0.63% of the total share capital of 771,634,398 shares[28] - The first release date for the restricted stocks under the 2023 incentive plan is set for July 21, 2025[29] - The company has approved 570,000 stock options for 22 eligible participants, representing 0.74% of the total share capital, with an exercise price of 2.84 yuan per share[30] Other Financial Metrics - Fair value gains increased by 134,289.65 yuan, a growth of 172.91% compared to the same period last year, primarily due to stock price recovery of other listed companies held by subsidiary Hangzhou Youben[16] - The company reported a net investment loss of ¥1,139,097.30 compared to a loss of ¥631,039.01 in the previous period[36] - The total operating revenue for the period reached ¥2,036,199,952.22, an increase of 22.9% compared to ¥1,657,273,697.64 in the previous period[36] - Total operating costs amounted to ¥1,893,954,187.39, up 23.7% from ¥1,530,578,504.10 in the prior period[36] - The company did not undergo an audit for the Q3 financial report[40]